Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
US Stock Futures Hold Steady as Iran Hormuz Deal and Earnings Shape Market Sentiment 
Oil Prices Surge as Iran Hormuz Restrictions Renew Supply Fears 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
Asian Stocks Mixed as Chip Selloff Hits KOSPI, Nikkei Ahead of US Jobs Data 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
US Job Growth Seen Picking Up in July 
Asian Stocks Slide as Semiconductor Selloff Weighs on South Korea and Japan 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Asian Stocks Cautious Ahead of US Jobs Data as Oil Rises 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
US Stock Futures Rise as Markets Await July Payrolls Data 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
